Literature DB >> 24492282

Increased expression of c-Jun in nonalcoholic fatty liver disease.

Christoph Dorn1, Julia C Engelmann2, Michael Saugspier1, Andreas Koch1, Arndt Hartmann3, Martina Müller1, Rainer Spang2, Anja Bosserhoff4, Claus Hellerbrand1.   

Abstract

Overnutrition is the major cause of nonalcoholic fatty liver disease (NAFLD) and its advanced form nonalcoholic steatohepatitis (NASH). We aimed to develop and characterize a murine model, which resembles both the pathology and nutritional situation, of NASH patients in Western societies. Mice were fed with a NASH-inducing diet (ND) containing sucrose, cholesterol and fats rich in saturated fatty acids in a composition, which mimics Western food. After 12 weeks, ND-fed mice revealed obesity and impaired glucose tolerance. In the liver, ND-feeding led to marked steatosis, hepatocellular damage, inflammation and beginning fibrosis. Transcriptome-wide gene expression analysis and search for over-represented transcription factor target sites among the differentially expressed genes identified activator protein-1 (AP-1) as the most likely factor to cause the transcriptional changes in ND livers. Combining differentially expressed gene and protein-protein interaction network analysis identified c-Jun as hub in the largest connected deregulated sub-network in ND livers. Accordingly, ND livers revealed c-Jun-phosphorylation and nuclear translocation. Moreover, hepatic c-Jun expression was enhanced in ND-fed mice. Combined tissue microarray technology and immunohistochemical analysis confirmed enhanced hepatic c-Jun levels in NAFLD patients, which correlated with inflammation, and notably, with the degree of hepatic steatosis. In summary, our new mouse model shows important pathological changes also found in human NASH and indicates c-Jun/AP-1 activation as critical regulator of hepatic alterations. Abundance of c-Jun in NAFLD likely facilitates development and progression of NASH.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24492282     DOI: 10.1038/labinvest.2014.3

Source DB:  PubMed          Journal:  Lab Invest        ISSN: 0023-6837            Impact factor:   5.662


  56 in total

Review 1.  Genetic vulnerability to diet-induced obesity in the C57BL/6J mouse: physiological and molecular characteristics.

Authors:  Sheila Collins; Tonya L Martin; Richard S Surwit; Jacques Robidoux
Journal:  Physiol Behav       Date:  2004-04

2.  Gene expression in human NAFLD.

Authors:  Dario Greco; Anna Kotronen; Jukka Westerbacka; Oscar Puig; Perttu Arkkila; Tuula Kiviluoto; Saara Laitinen; Maria Kolak; Rachel M Fisher; Anders Hamsten; Petri Auvinen; Hannele Yki-Järvinen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-04-03       Impact factor: 4.052

Review 3.  The role of fructose in the pathogenesis of NAFLD and the metabolic syndrome.

Authors:  Jung Sub Lim; Michele Mietus-Snyder; Annie Valente; Jean-Marc Schwarz; Robert H Lustig
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-04-06       Impact factor: 46.802

4.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

5.  Free fatty acid-induced inhibition of glucose and insulin-like growth factor I-induced deoxyribonucleic acid synthesis in the pancreatic beta-cell line INS-1.

Authors:  S P Cousin; S R Hügl; C E Wrede; H Kajio; M G Myers; C J Rhodes
Journal:  Endocrinology       Date:  2001-01       Impact factor: 4.736

Review 6.  Adipokines in inflammation and metabolic disease.

Authors:  Noriyuki Ouchi; Jennifer L Parker; Jesse J Lugus; Kenneth Walsh
Journal:  Nat Rev Immunol       Date:  2011-01-21       Impact factor: 53.106

Review 7.  JNK regulation of hepatic manifestations of the metabolic syndrome.

Authors:  Mark J Czaja
Journal:  Trends Endocrinol Metab       Date:  2010-10-01       Impact factor: 12.015

8.  MicroRNA miR-125b controls melanoma progression by direct regulation of c-Jun protein expression.

Authors:  M Kappelmann; S Kuphal; G Meister; L Vardimon; A-K Bosserhoff
Journal:  Oncogene       Date:  2012-07-16       Impact factor: 9.867

Review 9.  Does fructose consumption contribute to non-alcoholic fatty liver disease?

Authors:  Luc Tappy; Kim-Anne Lê
Journal:  Clin Res Hepatol Gastroenterol       Date:  2012-07-12       Impact factor: 2.947

10.  Liver NF-kappaB and AP-1 DNA binding in obese patients.

Authors:  Luis A Videla; Gladys Tapia; Ramón Rodrigo; Paulina Pettinelli; Daniela Haim; Catherine Santibañez; A Verónica Araya; Gladys Smok; Attila Csendes; Luis Gutierrez; Jorge Rojas; Jaime Castillo; Owen Korn; Fernando Maluenda; Juan C Díaz; Guillermo Rencoret; Jaime Poniachik
Journal:  Obesity (Silver Spring)       Date:  2009-01-22       Impact factor: 5.002

View more
  35 in total

1.  Bioinformatics Analysis of Key Differentially Expressed Genes in Nonalcoholic Fatty Liver Disease Mice Models.

Authors:  Chao Hou; Wenwen Feng; Shan Wei; Yulin Wang; Xiaoyi Xu; Jin Wei; Ziliang Ma; Yongsheng Du; Jialin Guo; Yu He; Fanyun Kong; Renxian Tang; Kuiyang Zheng
Journal:  Gene Expr       Date:  2018-08-22

2.  Cyclin D1 in the Liver: Role of Noncanonical Signaling in Liver Steatosis and Hormone Regulation.

Authors:  Kelley G Núñez; Janet Gonzalez-Rosario; Paul T Thevenot; Ari J Cohen
Journal:  Ochsner J       Date:  2017

Review 3.  Updates on Dietary Models of Nonalcoholic Fatty Liver Disease: Current Studies and Insights.

Authors:  Kristen Stephenson; Lindsey Kennedy; Laura Hargrove; Jennifer Demieville; Joanne Thomson; Gianfranco Alpini; Heather Francis
Journal:  Gene Expr       Date:  2017-11-02

4.  Phosphatidylcholine transfer protein/StarD2 promotes microvesicular steatosis and liver injury in murine experimental steatohepatitis.

Authors:  Hayley T Nicholls; Jason L Hornick; David E Cohen
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2017-04-06       Impact factor: 4.052

5.  Nonalcoholic fatty liver disease impairs expression of the type II inositol 1,4,5-trisphosphate receptor.

Authors:  Tanaporn Khamphaya; Natsasi Chukijrungroat; Vitoon Saengsirisuwan; Kisha A Mitchell-Richards; Marie E Robert; Albert Mennone; Meenakshisundaram Ananthanarayanan; Michael H Nathanson; Jittima Weerachayaphorn
Journal:  Hepatology       Date:  2018-01-02       Impact factor: 17.425

6.  Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Authors:  Tamara Vanhaecke; Robim M Rodrigues; Joost Boeckmans; Alessandra Natale; Matthias Rombaut; Karolien Buyl; Brent Cami; Veerle De Boe; Anja Heymans; Vera Rogiers; Joery De Kock
Journal:  Cell Biol Toxicol       Date:  2020-07-01       Impact factor: 6.691

7.  N-n-Butyl haloperidol iodide ameliorates liver fibrosis and hepatic stellate cell activation in mice.

Authors:  Dai-Fei Shen; He Cheng; Bo-Zhi Cai; Wen-Feng Cai; Bin Wang; Qing Zhu; Yue-Bin Wu; Man Liu; Run-Ji Chen; Fen-Fei Gao; Yan-Mei Zhang; Yong-Dong Niu; Gang-Gang Shi
Journal:  Acta Pharmacol Sin       Date:  2021-03-23       Impact factor: 6.150

8.  A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer.

Authors:  Takuma Tsuchida; Youngmin A Lee; Naoto Fujiwara; Maria Ybanez; Brittany Allen; Sebastiao Martins; M Isabel Fiel; Nicolas Goossens; Hsin-I Chou; Yujin Hoshida; Scott L Friedman
Journal:  J Hepatol       Date:  2018-03-21       Impact factor: 30.083

9.  Endogenously increased n-3 PUFA levels in fat-1 transgenic mice do not protect from non-alcoholic steatohepatitis.

Authors:  Marie Liebig; Dirk Dannenberger; Brigitte Vollmar; Kerstin Abshagen
Journal:  Hepatobiliary Surg Nutr       Date:  2019-10       Impact factor: 7.293

10.  Identification of Autophagy-Related Genes in the Progression from Non-Alcoholic Fatty Liver to Non-Alcoholic Steatohepatitis.

Authors:  Mengyao Ma; Wenhua Xie; Xi Li
Journal:  Int J Gen Med       Date:  2021-07-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.